VentriPoint Diagnostics Engages CHF Investor Relations and Reports Approval of Shares Issued to Directors and Consultants as Payment for Services

SEATTLE, Oct. 2 /CNW/ -- VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX Venture: VPT) announced today that, subject to TSX Venture Exchange approval, it has retained CHF Investor Relations (Cavalcanti Hume Funfer Inc., "CHF"), Canada's only IR firm whose management team's combined experience possesses more than 80 years covering brokerage, trading, financial analysis, and investment sales, over and above their work in IR.